Concurrence announced that its Health World Model and AI agents are now available in Microsoft Marketplace, letting customers discover and deploy them through that channel. The platform deploys directly into a healthcare organization's existing Azure environment without data migration and is interoperable with Epic on Azure and Microsoft Fabric. The Health World Model unifies patient data across EHR records, claims, labs, device data and more, while AI agents support tasks such as patient intake, medication management and clinical decision support. Purchases through Marketplace can be applied toward customers' Microsoft Azure Consumption Commitment (MACC).
Summary written by Upside AI from the original article. Read the source for full details.
Read the original on Yahoo Finance ↗
Keywords
MSFTartificial intelligencehealthcarecloud computing
Open a keyword to see other news on the same topic.
Related tickers and likely impact
MSFT
• NeutralMicrosoft
Relevance: low
| Market | US stocks |
|---|---|
| Sector | Information Technology |
| Industry | Systems Software |
| Market cap | $3.9T |
| Close on 10/28/2026 | 530.83 |
| Change that session | -0.09% |
Impact is scored by AI from the headline and may be wrong. It is not investment advice.
Related news
- UMass Memorial Health Announces Unified Data Platform Multi-Year Initiative, Investments in AI-Powered Innovation in Partnership with Accenture and Microsoft
UMass Memorial Health announced a multi-year initiative with Accenture (NYSE: ACN) and Microsoft to modernize its data platform, supporting care delivery, operations and AI-powered innovation. A unified platform on Microsoft Azure will replace siloed reporting systems, bringing the electronic health record and clinical, operational and research data into one connected platform. Accenture will introduce agentic AI tools to automate complex workflows, with goals including shorter patient length of stay and less administrative burden for caregivers. The transformation is expected to improve speed, quality and security while lowering long-term infrastructure costs, and to support greater data sharing and research with UMass Chan Medical School.
- Why Is Microsoft (MSFT) Central To AI Cyberattacks And Digital Patient Twins?
Microsoft reported that its threat intelligence teams helped uncover a Beijing-backed, AI-driven cyber campaign targeting several sensitive sectors in 2026. According to the company, attackers used generative AI tools to craft spear-phishing content and automate reconnaissance against government, defense and telecom organizations. Microsoft also announced a collaboration with Boehringer Ingelheim to use Azure-powered AI “digital patient twins” in clinical trials and drug development. The article argues these developments give Microsoft direct visibility into enterprise cyber risks and large-scale AI workloads, while raising the question of whether heavy AI and data center spending is matched by security. The next test, it says, is whether upcoming quarterly disclosures show how many large regulated customers are using Microsoft's AI tools in production rather than only piloting them.
- Boehringer and Microsoft collaborate to explore AI in clinical research
Boehringer Ingelheim and Microsoft have launched a strategic collaboration to explore AI in clinical research, starting with lung health studies. The focus is on digital patient twins, computer-based models of individual patients built from clinical data, to test whether they can forecast disease progression and patient outcomes. The companies will assess whether these models can serve as synthetic or hybrid control arms, potentially reducing the number of participants in control groups, streamlining trial design and speeding up evidence generation. If successful, the approach could improve drug development efficiency and allow more trial participants to receive experimental treatments. The alliance also covers data centre modernisation and technical security, with further joint initiatives under review in animal health and commercial processes.
- Tucuvi joins the Microsoft Pegasus Program to scale clinically governed AI Care Management across health systems
Tucuvi, an AI care management company, has joined the Microsoft for Startups Pegasus Program to bring its clinically governed AI platform to more health systems. Its core product, LOLA®, is a clinical voice AI agent that handles inbound and outbound patient calls, follows configured clinical and administrative protocols, and escalates cases to human clinicians when needed. The platform is already used by more than 80 health settings across 50+ workflow types and is certified as Class IIb Software as a Medical Device in the European Union. Health systems can buy through Microsoft Marketplace or apply spend against their existing Microsoft Azure commitments.
- Wall Street's top analysts are loving Microsoft's Q1 results
Microsoft reported first-quarter earnings of $4.89 per share on revenue of $92.28 billion, above Bloomberg consensus estimates of $4.73 and $90.63 billion, though the stock fell more than 1% after the bell. Azure revenue grew 48% year over year to $33.17 billion, which analysts highlighted as the strongest part of the report. TD Cowen raised its fiscal 2027 Azure growth estimate to 48% from 43% and its price target to $650 from $625, while Cantor lifted its target to $630 from $608 and Citizens raised its target to $625 from $550. Citizens also noted that consumer business revenue fell 3%, while BofA reaffirmed its rating and raised its price target to $630 from $600.
- Microsoft's Positioning Across Infrastructure, Software Provides Multiple AI Monetization Paths, BofA Says
Related markets
Latest news
- Oracle Is Up 12% in a Week. Is Its Free Cash Flow Plan Really That Good?
Oracle shares rose 12% over the past week after its Investor Day, where the company said it expects positive free cash flow in the second half of fiscal 2028 and over $30 billion in fiscal 2029, versus a consensus of $5.9 billion. New capital raises through fiscal 2030 are capped at $20 billion, less than half the $50 billion to $60 billion Evercore estimated for its AI buildout. The main risk cited is that S&P puts OpenAI at about half of Oracle's backlog. With forward earnings at about 17x versus a 21x five-year average, the author takes a positive view of Oracle for patient investors, with second-quarter results in mid-December as the first test.
- Amazon earnings live: AI growth takes center stage
Amazon (AMZN) will report third-quarter results on Thursday, a day after Google (GOOG, GOOGL) posted disappointing earnings that sent its shares down more than 12%. Microsoft (MSFT), which reported better-than-expected results on Wednesday, saw its stock rise. According to Bloomberg analyst consensus, Amazon is projected to post EPS of $1.97 on revenue of $202.25 billion, versus EPS of $1.95 and revenue of $180.16 billion a year earlier. AWS revenue is expected at $45.68 billion, up 38% from $33 billion in Q3 2025, with online store sales at $69.6 billion (up 3%) and advertising at $20.91 billion (up 18%). Investors will also watch capital expenditures tied to the AI buildout; a pullback could lift Amazon's stock but pressure the broader AI industry, including chipmakers and neocloud providers.
- Aon CEO warns AI data center insurance risks could threaten financing
Aon CEO Greg Case warned in a CNBC interview that concentrating billions of dollars of AI equipment and computing capacity in a few locations creates concentration risk that could make projects harder to insure and force financing structures to change. He said data center business interruption could be measured in millions of dollars per minute. Aon reported a record data center project pipeline, 7% organic revenue growth in its commercial risk business, and adjusted EPS up 10% to $3.36 in the third quarter. Aon's pending $17 billion acquisition of USI Insurance Services, expected to close in the fourth quarter, is expected to bring $395 million in annual earnings benefits. Case believes the global insurance industry's roughly $4.5 trillion in capital must double or triple to meet growing cyber, AI and data center risks.
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
Eli Lilly shares rose over 6% to about $1,370, a record closing high, after third-quarter revenue jumped 39% year over year to $24.4 billion, above the LSEG consensus of $22.6 billion. Adjusted EPS rose 6.6% to $7.48, beating analysts' $6.26 estimate, though a sizable acquisition-related accounting charge held back annual profit growth. Adjusted gross margin reached 84.4%, up from 83.6% a year earlier. Mounjaro revenue climbed 65% to $10.7 billion and Zepbound rose 49% to $5.35 billion, as higher patient volumes more than offset lower realized prices. The price target was raised to $1,500 from $1,300 and the 2 rating was reiterated, with shares up more than 50% since the April 29 close.
- AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,000
AbbVie was spun off from Abbott Laboratories on January 1, 2013, and relied heavily on Humira until the drug lost U.S. exclusivity in early 2023. In Q2 2026, Humira sales fell 35.9% to $756 million, while Skyrizi rose 24.4% to $5.505 billion and Rinvoq rose 24.5% to $2.525 billion. The quarterly dividend grew from $0.57 in 2016 to $1.73, with a forward annual dividend of $6.92 and a yield of roughly 2.30%. A $1,000 investment 10 years ago would be worth $7,464.50 including dividends, a 646.45% total return, versus 263.37% for the S&P 500 on a price-only basis. The article notes the shares closed at $197.99 on April 29, 2026, reached about $291.48 this morning, and trade above the average analyst target of $283.19, while also flagging negative shareholders' equity and a forward P/E of about 18.
- $11 Billion in Bitcoin Options Expire Tomorrow—Here's What It Means
About $11 billion in Bitcoin options, roughly 135,000 BTC and a third of Deribit's Bitcoin options open interest, expire on Friday. Max pain sits at $78,000 against a market price near $81,500, and about 86% of contracts are out of the money. The Fed held rates at 3.75% to 4% on Wednesday in a 10-2 vote, with two dissenters favoring a hike, while the 10-year Treasury yield closed at 5.05%. Of the expiring contracts, roughly 88,700 are calls and 46,500 are puts, a put-to-call ratio of 0.52. Because the $11 billion is notional value, settling at today's price would move about $130 million, roughly 1% of the headline figure. Heaviest call strikes sit at $95,000 and $100,000, with the biggest put cluster at $70,000, and the next expiry on December 25 covers about 135,500 BTC.
Get the briefing on Telegram or Zalo
Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.